ArticleBMC cancer2021

Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.

Xia Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.